What is it about?

The aim of this study was to investigate the feasibility of employing S-carboxymethyl-l-cysteine as a treatment of chronic obstructive pulmonary disease in dogs. To this end the pharmacokinetic parameters of orally administered S-carboxymethyl-l-cysteine were determined in the dog, cow and sheep. Six healthy beagle dogs, six endogenous Greek sheep and four Holstein Fresian calves were orally dosed with 10 mg/kg body weight of S-carboxymethyl-l-cysteine. No significant differences in Tmax and T1/2 were reported between the species. However, significantly higher AUC(0–last), 21.56±6.67ghml−1 and AUC(0–∞), 21.63±6.68ghml−1 were seen in the dogs compared to the sheep and calves. The calculated VD was significantly higher in the sheep (10.4±2.7Lkg−1) and the calves (3.8±0.7Lkg−1) compared to the dogs (1.0±0.6Lkg−1). The rank order of increasing CL was sheep (3.4±2.7Lh−1 kg−1) > calves (2.7±0.4Lh−1 kg−1) > dogs (0.5±0.2Lh−1 kg−1). The result for the dogs was significantly lower that the calculated CL for the sheep and calves. All these results indicate that the oral administration of S-carboxymethyl-l-cysteine may be useful during the therapeutic management of chronic obstructive pulmonary disease in dogs.

Featured Image

Why is it important?

The fists reports of the pharmacokinetics of S-carboxymethyl-l-cysteine in dogs, sheep and cows.

Read the Original

This page is a summary of: The pharmacokinetics of orally administered S-carboxymethyl-l-cysteine in the dog, calf and sheep, European Journal of Pharmaceutical Sciences, February 2010, Elsevier, DOI: 10.1016/j.ejps.2009.12.003.
You can read the full text:



Be the first to contribute to this page